Amy R Baugher, Cyprian Wejnert, Dafna Kanny, Dita Broz, Jonathan Feelemyer, Rebecca B Hershow, Janet Burnett, Johanna Chapin-Bardales, Maya Haynes, Teresa Finlayson, Joseph Prejean
{"title":"我们是否结束了艾滋病毒在注射吸毒者中的流行？： 2022年美国19个城市的主要调查结果。","authors":"Amy R Baugher, Cyprian Wejnert, Dafna Kanny, Dita Broz, Jonathan Feelemyer, Rebecca B Hershow, Janet Burnett, Johanna Chapin-Bardales, Maya Haynes, Teresa Finlayson, Joseph Prejean","doi":"10.1097/QAD.0000000000004249","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>National HIV Behavioral Surveillance (NHBS) conducts surveillance among key populations, including persons who inject drugs (PWID). NHBS data can be used to monitor progress toward national goals, including Ending the HIV Epidemic (EHE). EHE strategies include HIV testing (Diagnose), rapid linkage to HIV treatment (Treat), and increasing access to pre-exposure prophylaxis (PrEP) and syringe services programs (SSPs) (Prevent). This analysis aimed to concisely compare NHBS key findings among PWID to EHE goals.</p><p><strong>Design/methods: </strong>Cross-sectional NHBS data were collected from PWID in 2018 (n = 9,786) and 2022 (n = 6,574) in 19 U.S. cities. We compared key findings from 2022 NHBS to 1) specified EHE goals for Diagnose (HIV testing) and Treat (linkage to care, current antiretroviral therapy (ART) use) or 2) 2018 NHBS key findings for Prevent (PrEP and SSP use).</p><p><strong>Results: </strong>In 2022, 45% of PWID were tested for HIV; 45% of PWID with HIV were linked to care within 1 month of diagnosis, and 79% were currently taking ART; 1% of PWID without HIV used PrEP; and approximately half of all PWID received syringes from an SSP. PrEP and SSP use among PWID have not changed since 2018.</p><p><strong>Conclusions: </strong>National HIV strategies are not yet adequately reaching PWID. To end the U.S. HIV epidemic, multi-level solutions are needed to tailor interventions for PWID and dismantle barriers to testing, treatment, and prevention. Structural solutions to improve access to basic needs and SSPs may have downstream benefits across the EHE strategies.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Are we ending the HIV epidemic among persons who inject drugs?: Key findings from 19 U.S. cities, 2022.\",\"authors\":\"Amy R Baugher, Cyprian Wejnert, Dafna Kanny, Dita Broz, Jonathan Feelemyer, Rebecca B Hershow, Janet Burnett, Johanna Chapin-Bardales, Maya Haynes, Teresa Finlayson, Joseph Prejean\",\"doi\":\"10.1097/QAD.0000000000004249\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>National HIV Behavioral Surveillance (NHBS) conducts surveillance among key populations, including persons who inject drugs (PWID). NHBS data can be used to monitor progress toward national goals, including Ending the HIV Epidemic (EHE). EHE strategies include HIV testing (Diagnose), rapid linkage to HIV treatment (Treat), and increasing access to pre-exposure prophylaxis (PrEP) and syringe services programs (SSPs) (Prevent). This analysis aimed to concisely compare NHBS key findings among PWID to EHE goals.</p><p><strong>Design/methods: </strong>Cross-sectional NHBS data were collected from PWID in 2018 (n = 9,786) and 2022 (n = 6,574) in 19 U.S. cities. We compared key findings from 2022 NHBS to 1) specified EHE goals for Diagnose (HIV testing) and Treat (linkage to care, current antiretroviral therapy (ART) use) or 2) 2018 NHBS key findings for Prevent (PrEP and SSP use).</p><p><strong>Results: </strong>In 2022, 45% of PWID were tested for HIV; 45% of PWID with HIV were linked to care within 1 month of diagnosis, and 79% were currently taking ART; 1% of PWID without HIV used PrEP; and approximately half of all PWID received syringes from an SSP. PrEP and SSP use among PWID have not changed since 2018.</p><p><strong>Conclusions: </strong>National HIV strategies are not yet adequately reaching PWID. To end the U.S. HIV epidemic, multi-level solutions are needed to tailor interventions for PWID and dismantle barriers to testing, treatment, and prevention. Structural solutions to improve access to basic needs and SSPs may have downstream benefits across the EHE strategies.</p>\",\"PeriodicalId\":7502,\"journal\":{\"name\":\"AIDS\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-06-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AIDS\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/QAD.0000000000004249\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/QAD.0000000000004249","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Are we ending the HIV epidemic among persons who inject drugs?: Key findings from 19 U.S. cities, 2022.
Objectives: National HIV Behavioral Surveillance (NHBS) conducts surveillance among key populations, including persons who inject drugs (PWID). NHBS data can be used to monitor progress toward national goals, including Ending the HIV Epidemic (EHE). EHE strategies include HIV testing (Diagnose), rapid linkage to HIV treatment (Treat), and increasing access to pre-exposure prophylaxis (PrEP) and syringe services programs (SSPs) (Prevent). This analysis aimed to concisely compare NHBS key findings among PWID to EHE goals.
Design/methods: Cross-sectional NHBS data were collected from PWID in 2018 (n = 9,786) and 2022 (n = 6,574) in 19 U.S. cities. We compared key findings from 2022 NHBS to 1) specified EHE goals for Diagnose (HIV testing) and Treat (linkage to care, current antiretroviral therapy (ART) use) or 2) 2018 NHBS key findings for Prevent (PrEP and SSP use).
Results: In 2022, 45% of PWID were tested for HIV; 45% of PWID with HIV were linked to care within 1 month of diagnosis, and 79% were currently taking ART; 1% of PWID without HIV used PrEP; and approximately half of all PWID received syringes from an SSP. PrEP and SSP use among PWID have not changed since 2018.
Conclusions: National HIV strategies are not yet adequately reaching PWID. To end the U.S. HIV epidemic, multi-level solutions are needed to tailor interventions for PWID and dismantle barriers to testing, treatment, and prevention. Structural solutions to improve access to basic needs and SSPs may have downstream benefits across the EHE strategies.
期刊介绍：
Publishing the very latest ground breaking research on HIV and AIDS. Read by all the top clinicians and researchers, AIDS has the highest impact of all AIDS-related journals. With 18 issues per year, AIDS guarantees the authoritative presentation of significant advances. The Editors, themselves noted international experts who know the demands of your work, are committed to making AIDS the most distinguished and innovative journal in the field. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
